| Literature DB >> 29729778 |
Abstract
Neuropathic pain is the result of neuroplastic and neuroinflammatory changes from trauma or diseases that damage the somatosensory system. Cancer-related neuropathic pain is caused by treatment, cancer, or paraneoplastic reactions to cancer. Approximately 30% of patients with cancer have neuropathic pain, mostly mixed nociceptive and neuropathic pain. History, physical examination, quantitative sensory testing, skin punch biopsies, and functional MRIs help to divide pain into phenotypes that may facilitate analgesic choices. Guidelines for treating cancer-related neuropathic pain are not consistent and are highly dependent on trials in patients without cancer. Combinations of analgesics are promising, whereas evidence for cannabinoids is meager.Entities:
Keywords: Analgesics; Cannabinoids; Neuroinflammation; Neuropathic; Neuroplasticity; Pain
Mesh:
Year: 2018 PMID: 29729778 DOI: 10.1016/j.hoc.2018.01.005
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722